<code id='C55A508C7A'></code><style id='C55A508C7A'></style>
    • <acronym id='C55A508C7A'></acronym>
      <center id='C55A508C7A'><center id='C55A508C7A'><tfoot id='C55A508C7A'></tfoot></center><abbr id='C55A508C7A'><dir id='C55A508C7A'><tfoot id='C55A508C7A'></tfoot><noframes id='C55A508C7A'>

    • <optgroup id='C55A508C7A'><strike id='C55A508C7A'><sup id='C55A508C7A'></sup></strike><code id='C55A508C7A'></code></optgroup>
        1. <b id='C55A508C7A'><label id='C55A508C7A'><select id='C55A508C7A'><dt id='C55A508C7A'><span id='C55A508C7A'></span></dt></select></label></b><u id='C55A508C7A'></u>
          <i id='C55A508C7A'><strike id='C55A508C7A'><tt id='C55A508C7A'><pre id='C55A508C7A'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

          Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

          advertisement

          Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge